Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flurbiprofen for Cough Hypersensitivity in URTI
NCT05955885Phase 1Completed
- Sponsor
- University of Melbourne
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of flurbiprofen in cough and upper respiratory tract infection (URI) (4 arms), sponsored by University of Melbourne. Primary endpoint: Change in objective measures of cough sensitivity at 3 hours. Started Jul 2023; status: completed.
02
Drugs
flurbiprofen
03
Conditions
coughupper respiratory tract infection (URI)
Beyond the preview
Go deeper on NCT05955885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955885.